A recent retrospective cohort analysis suggests that five decades of aggressive federal narcotics enforcement has yielded statistically significant, albeit unintended, improvements to the affordability and potency of illicit street drugs. Researchers warn that these consumer-friendly pricing models require immediate further study.
A paper published Tuesday in The Lancet examined street-level narcotics pricing in Baltimore, finding that billions of dollars in federal interdiction efforts are strongly associated with a highly optimized, hyper-efficient illicit drug market. While the authors stressed that causation cannot be definitively proven, the data indicates a robust correlation between aggressive Drug Enforcement Administration funding and catastrophic improvements in the delivery logistics of ultrapotent synthetics.
The study’s lead researchers emphasized that their findings rely heavily on self-reported purchasing data from a relatively small cohort of Baltimore residents, and thus should be interpreted with extreme caution. However, initial modeling suggests the War on Drugs has served as a primary risk factor for making illicit substances vastly cheaper and exponentially more powerful than they were prior to the intervention.
While we must acknowledge the limitations of observational data, it appears the federal government's primary achievement over the last half-century has been inadvertently subsidizing the research and development of ultrapotent opioids.
Experts caution that more research is needed to fully understand how illicit drug manufacturers managed to outpace FDA-approved pharmaceutical companies in both manufacturing efficiency and distribution. Preliminary findings suggest that bypassing the peer-review process entirely allowed international cartels to rapidly iterate on chemical structures, though this protocol naturally lacks longitudinal safety data and raises several ethical concerns regarding patient mortality.
The CDC has issued updated guidance recommending that policymakers exercise extreme caution before launching any further multi-decade, trillion-dollar wars on complex societal problems, pending a double-blind, randomized controlled trial to ensure they do not accidentally optimize them.